What is Zacks Research's Forecast for JNJ Q2 Earnings?

Johnson & Johnson (NYSE:JNJ - Free Report) - Analysts at Zacks Research decreased their Q2 2025 EPS estimates for Johnson & Johnson in a research note issued on Wednesday, April 30th. Zacks Research analyst K. Shah now expects that the company will post earnings per share of $2.64 for the quarter, down from their prior estimate of $2.69. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson's Q3 2025 earnings at $2.73 EPS and Q4 2026 earnings at $2.78 EPS.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion.

A number of other research firms have also commented on JNJ. Barclays lowered their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Stifel Nicolaus decreased their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Morgan Stanley upped their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Raymond James reduced their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Finally, Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $171.82.

Johnson & Johnson Stock Down 1.4 %

Shares of Johnson & Johnson stock traded down $2.21 during trading hours on Monday, reaching $155.09. The company's stock had a trading volume of 936,487 shares, compared to its average volume of 7,865,650. The company has a market capitalization of $373.16 billion, a P/E ratio of 23.32, a P/E/G ratio of 2.56 and a beta of 0.42. The stock's fifty day simple moving average is $158.35 and its two-hundred day simple moving average is $154.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Institutional Trading of Johnson & Johnson

Institutional investors have recently bought and sold shares of the company. MRP Capital Investments LLC lifted its position in Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after acquiring an additional 65 shares in the last quarter. Syverson Strege & Co boosted its position in shares of Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after buying an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management increased its holdings in Johnson & Johnson by 3.3% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after buying an additional 66 shares in the last quarter. Denali Advisors LLC lifted its stake in Johnson & Johnson by 1.3% during the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after acquiring an additional 67 shares during the period. Finally, Sage Mountain Advisors LLC grew its stake in shares of Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after acquiring an additional 67 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.35%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.